Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Combo Therapy for Myelodysplastic Syndromes Misses Survival Goal in Randomized Trial

Summary by MedPage Today
(MedPage Today) -- HOUSTON -- Survival in untreated, intermediate- and higher-risk myelodysplastic syndromes (MDS) failed to improve with the addition of the targeted agent venetoclax (Venclexta) to chemotherapy, a large randomized trial showed...

3 Articles

MedPage TodayMedPage Today
Reposted by
Anti-Aging, Acupuncture and Health NewsAnti-Aging, Acupuncture and Health News
Center

Combo Therapy for Myelodysplastic Syndromes Misses Survival Goal in Randomized Trial

(MedPage Today) -- HOUSTON -- Survival in untreated, intermediate- and higher-risk myelodysplastic syndromes (MDS) failed to improve with the addition of the targeted agent venetoclax (Venclexta) to chemotherapy, a large randomized trial showed...

·New York, United States
Read Full Article
curetoday.comcuretoday.com

Venclexta And Azacitidine Fail to Improve MDS Survival

Results from the phase 3 VERONA trial were presented at the 2025 Society of Hematologic Oncology Annual Meeting.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

curetoday.com broke the news in on Friday, September 5, 2025.
Sources are mostly out of (0)

Similar News Topics

Houston, Texas icon

Houston, Texas

News
For You
SearchBlindspotLocal